Drug Type Antibody drug conjugate (ADC) |
Synonyms BVX 100 vcMMAE, BVX 001, BVX-001 |
Target |
Mechanism CD33 inhibitors(Myeloid cell surface antigen CD33 inhibitors), CD7 inhibitors(T-cell antigen CD7 inhibitors), Tubulin inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC11H22N4O4 |
InChIKeyAGGWFDNPHKLBBV-YUMQZZPRSA-N |
CAS Registry159858-33-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | GB | 12 Sep 2023 | |
Acute Myeloid Leukemia | Preclinical | GB | - |